Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Albumin peptides are short chains of amino acids derived from the enzymatic or chemical hydrolysis of albumin, a major plasma protein primarily produced by the liver. Unlike intact human serum albumin (HSA), which is used therapeutically as a plasma expander and for treating hypoalbuminemia and hypovolemia[1][2][3], "albumin peptides" refers specifically to smaller peptide fragments generated from the parent protein. These peptides may be investigated or marketed as dietary supplements for their potential bioactive properties such as antioxidant activity, modulation of immune response, or support in muscle recovery. They are not standard pharmaceutical drugs but rather fall under the category of functional food ingredients or nutraceuticals. Their mechanism is generally attributed to their ability to interact with biological pathways through antioxidant effects and possible signaling functions; however, they do not act via a single defined pharmacological target like intact therapeutic human serum albumin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on albumin peptides.